Since its establishment in 2022, WUXI EXTPURE has focused on the research and development of the underlying purification process and products for cell gene therapy. In terms of quality management, the company has passed the ISO9001 quality management system certification, has a mature production process and a standardized quality inspection system to ensure the reliability and stability of the products and meet the batch and quality requirements of industrial-grade customers. Supported by the listed company Quechen Silicon Chemical Co., Ltd. (stock code: 605183) as a strategic investor. As a listed company, Quechen shares, with its professional capabilities and market influence in the field of materials science, provides valuable resources and platforms for WUXI EXTPURE's technological innovation and market expansion. The QCC product series is the result of the joint research and development of Q&C and C&C (WUXI EXTPURE), reflecting the company's commitment to environmental protection and technological innovation. Through cooperation with Quechen shares, WUXI EXTPURE will further strengthen its competitive position in the market and provide customers with better quality and more stable products and services. The company's R&D team is composed of experts from well-known academic institutions at home and abroad such as Tsinghua University, with multidisciplinary backgrounds in physics, materials chemistry, biology, etc. The team has made remarkable achievements in the field of nucleic acid and virus purification technology, successfully overcame multiple technical challenges, and achieved a comprehensive technical layout.

The company's flagship products include:

1. ACC (Affinity Convective Chromatography): an innovative affinity convection chromatography column that provides efficient purification solutions for the biopharmaceutical industry.

2. CC (Convective Chromatography): a leading convection chromatography column in China, with advantages in the fields of mRNA therapy and personalized tumor vaccines, and plans to expand production scale from 2026 to 2027.

3. QCC (silica microspheres): prepared by an environmentally friendly non-sacrificial template emulsification method, committed to reducing the carbon footprint of products.

The company is committed to promoting the development of ACC affinity convection chromatography in the field of cell gene therapy purification through technological innovation and product optimization. WUXI EXTPURE will continue to be driven by innovation, provide customers with high-quality products and services, and promote progress in the field of biotechnology. At the same time, the company plans to expand its R&D team, and it is expected that the proportion of R&D personnel will reach 50-60% to ensure continued innovation and leadership in the field of biopurification.